PL3448430T3 - Zastosowanie inhibitora acetylocholinosterazy i idalopirydyny do ograniczania upadków u pacjentów z chorobą parkinsona - Google Patents

Zastosowanie inhibitora acetylocholinosterazy i idalopirydyny do ograniczania upadków u pacjentów z chorobą parkinsona

Info

Publication number
PL3448430T3
PL3448430T3 PL17719255.6T PL17719255T PL3448430T3 PL 3448430 T3 PL3448430 T3 PL 3448430T3 PL 17719255 T PL17719255 T PL 17719255T PL 3448430 T3 PL3448430 T3 PL 3448430T3
Authority
PL
Poland
Prior art keywords
idalopyridine
acetylcholinosterase
parkinson
inhibitor
patients
Prior art date
Application number
PL17719255.6T
Other languages
English (en)
Inventor
Inge E M De Jong
Aaron Kucinski
Martin Sarter
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of PL3448430T3 publication Critical patent/PL3448430T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17719255.6T 2016-04-26 2017-04-25 Zastosowanie inhibitora acetylocholinosterazy i idalopirydyny do ograniczania upadków u pacjentów z chorobą parkinsona PL3448430T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600248 2016-04-26
PCT/EP2017/059739 WO2017186686A1 (en) 2016-04-26 2017-04-25 Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Publications (1)

Publication Number Publication Date
PL3448430T3 true PL3448430T3 (pl) 2023-08-21

Family

ID=58632402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17719255.6T PL3448430T3 (pl) 2016-04-26 2017-04-25 Zastosowanie inhibitora acetylocholinosterazy i idalopirydyny do ograniczania upadków u pacjentów z chorobą parkinsona

Country Status (28)

Country Link
US (1) US10383849B2 (pl)
EP (1) EP3448430B1 (pl)
JP (1) JP6992004B2 (pl)
KR (1) KR102473545B1 (pl)
CN (3) CN109069650A (pl)
AU (1) AU2017256623B2 (pl)
BR (1) BR112017026928B1 (pl)
CA (1) CA3020557C (pl)
CL (1) CL2018003013A1 (pl)
CY (1) CY1126138T1 (pl)
DK (1) DK3448430T3 (pl)
ES (1) ES2949288T3 (pl)
FI (1) FI3448430T3 (pl)
HR (1) HRP20230693T8 (pl)
HU (1) HUE062626T2 (pl)
IL (1) IL262546B (pl)
LT (1) LT3448430T (pl)
MX (1) MX387444B (pl)
PL (1) PL3448430T3 (pl)
PT (1) PT3448430T (pl)
RS (1) RS64307B1 (pl)
RU (1) RU2742173C2 (pl)
SG (1) SG11201809297UA (pl)
SI (1) SI3448430T1 (pl)
SM (1) SMT202300197T1 (pl)
TW (1) TW201806621A (pl)
WO (1) WO2017186686A1 (pl)
ZA (1) ZA201806864B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909895UA (en) 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
EP3727043A4 (en) * 2017-12-22 2021-07-07 Neurocea, LLC COMPOSITIONS AND METHODS OF TREATMENT IN CONNECTION WITH THE CASE AND FREQUENCY OF NEURODEGENERATIVE DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
CZ305838B6 (cs) * 2001-03-29 2016-04-06 Eli Lilly And Company N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
CA2603258A1 (en) * 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
ATE509636T1 (de) * 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
RU2393158C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
SI3448430T1 (sl) 2023-08-31
JP2019519480A (ja) 2019-07-11
CA3020557C (en) 2024-05-21
CN118806910A (zh) 2024-10-22
MX387444B (es) 2025-03-18
EP3448430B1 (en) 2023-06-07
RU2018135846A3 (pl) 2020-09-30
SMT202300197T1 (it) 2023-09-06
EP3448430A1 (en) 2019-03-06
PT3448430T (pt) 2023-07-11
CY1126138T1 (el) 2023-11-15
BR112017026928B1 (pt) 2023-04-11
WO2017186686A1 (en) 2017-11-02
US20170304267A1 (en) 2017-10-26
BR112017026928A2 (pt) 2018-08-14
KR102473545B1 (ko) 2022-12-01
ZA201806864B (en) 2020-01-29
RU2018135846A (ru) 2020-05-26
ES2949288T3 (es) 2023-09-27
CA3020557A1 (en) 2017-11-02
CN118806909A (zh) 2024-10-22
CN109069650A (zh) 2018-12-21
LT3448430T (lt) 2023-07-25
KR20180133869A (ko) 2018-12-17
CL2018003013A1 (es) 2018-12-14
RU2742173C2 (ru) 2021-02-02
FI3448430T3 (fi) 2023-06-20
HRP20230693T8 (hr) 2023-11-10
RS64307B1 (sr) 2023-07-31
US10383849B2 (en) 2019-08-20
AU2017256623A1 (en) 2018-11-01
DK3448430T3 (da) 2023-07-03
AU2017256623B2 (en) 2022-07-21
HUE062626T2 (hu) 2023-11-28
TW201806621A (zh) 2018-03-01
IL262546B (en) 2022-05-01
JP6992004B2 (ja) 2022-02-03
IL262546A (en) 2018-12-31
HRP20230693T1 (hr) 2023-10-13
SG11201809297UA (en) 2018-11-29
MX2018013031A (es) 2019-01-17

Similar Documents

Publication Publication Date Title
CY2023010I1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
IL232256A0 (en) Novel purine derivatives and their use in the treatment of disease
SI3240554T1 (sl) Blautia stercosis in wexlerae za uporabo v zdravljenju vnetnih in avtoimunskih bolezni
IL239923A0 (en) Solid solution compositions and use in cardiovascular disease
SI3352584T1 (sl) Sestavki in postopki za sintezo 5'-omejenih RNAjev
PL2970101T5 (pl) Proleki fumaranów i ich zastosowanie w leczeniu różnych chorób
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
TWD191254S (zh) 槓鈴護套
EP2793993A4 (en) RECOVERY AND PROCESSING OF HUMAN IN VIVO EMBRYOS
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
DK3381451T3 (da) Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
IL280827A (en) Integrin alpha 4 antagonists and compositions comprising same for use in treating ocular conditions
PL3085786T3 (pl) Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych
EP3376977A4 (en) RECOVERY AND PROCESSING OF HUMAN EMBRYOS MADE IN VIVO
CL2014000833A1 (es) Composicion para ser usada en la promocion del crecimiento de hueso sano y/o en la prevencion y/o tratamiento de la enfermedad osea
PT3681857T (pt) Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia
EP2983661A4 (en) FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHENDS
PT3373922T (pt) Composições e métodos para usar no tratamento de homocistinúria
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
EP2853591A4 (en) HEMATOMIC HEMAZONE CELL LINE HLCZ01 AND USES THEREOF
EP3562400A4 (en) COMPUTER ASSISTED TOMOGRAPHY AND POSITIONING OF THE ANATOMY TO IMAGINE
PL3448430T3 (pl) Zastosowanie inhibitora acetylocholinosterazy i idalopirydyny do ograniczania upadków u pacjentów z chorobą parkinsona
DK3010543T3 (da) Terapeutiske midler til anvendelse i profylakse og/eller behandling af hyperkinetiske bevægelsesforstyrrelser